Long-Term Bezafibrate Treatment Improves Skin and Spleen Phenotypes of the mtDNA Mutator Mouse | PLOS ONE
Bezafibrate enhances proliferation and differentiation of osteoblastic MC3T3-E1 cells via AMPK and eNOS activation | Acta Pharmacologica Sinica
Bezafibrate Mildly Stimulates Ketogenesis and Fatty Acid Metabolism in Hypertriglyceridemic Subjects | Journal of Pharmacology and Experimental Therapeutics
Fibrates Art 31 referral - CHMP Assessment Report (for publication)
SANDOZ BEZAFIBRATE 400MG TAB 30 Your online pharmacy
Diagnosis and treatment of primary biliary cholangitis - Laschtowitz - 2020 - United European Gastroenterology Journal - Wiley Online Library
P023 The effective use of bezafibrate as a second line therapy for primary biliary cholangitis | Gut
Diagnosis and treatment of primary biliary cholangitis - Alena Laschtowitz, Rozanne C de Veer, Adriaan J Van der Meer, Christoph Schramm, 2020
Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor α-Independent Mechanism | Molecular Pharmacology
Atorvastatin Versus Bezafibrate in Mixed Hyperlipidaemia
Bezalip Retard (Bezafibrate) - United Pharmacies
Ursodeoxycholic acid and bezafibrate were useful for steroid-refractory, immune-related hepatitis: a case report | Journal of Medical Case Reports | Full Text
JCM | Free Full-Text | The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities
Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ12,14,PGJ2 | Leukemia
Bezafibrate at Clinically Relevant Doses Decreases Serum/Liver Triglycerides via Down-Regulation of Sterol Regulatory Element-Binding Protein-1c in Mice: A Novel Peroxisome Proliferator-Activated Receptor α-Independent Mechanism | Molecular Pharmacology
DYNA-BEZAFIBRATE SR 400 mg - Pharma Dynamics
Biomedicines | Free Full-Text | Clinically Relevant Dose of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα), Lowers Serum Triglyceride Levels by Targeting Hepatic PPARα in Mice
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis | NEJM
A) Dose response curve of bezafibrate and its EC 50 value. (B)... | Download Scientific Diagram
LOW DOSES OF FENOFIBRATE AND BEZAFIBRATE STIMULATE RENAL 2-OXOGLUTARATE DEHYDROGENASE (2-OGDH) IN PROTEIN-RESTRICTED RATS
Intercept Reports First Patient Dosing of Obeticholic Acid + Bezafibrate in the P-II Study for the Treatment of Primary Biliary Cholangitis
View of Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials | Annals of Gastroenterology
CLINICAL CHARACTERISTICS OF BEZAFIBRATE AND PLACEBO TREATED... | Download Table
Bezafibrate treatment prevented lipid vacuoles and activated... | Download Scientific Diagram
